[Monoamine oxidase inhibitors in psychiatry. Status of current knowledge].
With the introduction of moclobemide as the first reversible and selective inhibitor of monoamine oxidase (type A), the therapeutic principle of monoamine oxidase inhibition gained new importance. In this paper the clinical pharmacology, efficacy and side effects of traditional monoamine oxidase inhibitors and specifically of tranylcypromine as an example) are compared with those of the reversible and selective monoamine oxidase inhibitors (as exemplified by moclobemide).
Volz
H P
HP
Psychiatrische Klinik, Friedrich-Schiller-Universität, Jena.
Gleiter
C H
CH
Möller
H J
HJ
D000928:Antidepressive Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001549:Benzamides / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D003866:Depressive Disorder / Q000188:drug therapy* / Q000201:enzymology / Q000523:psychology; D006801:Humans; D020912:Moclobemide; D008995:Monoamine Oxidase / Q000097:blood; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D014191:Tranylcypromine / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use
D000928:Antidepressive Agents; D001549:Benzamides; D008996:Monoamine Oxidase Inhibitors; D014191:Tranylcypromine; D008995:Monoamine Oxidase; D020912:Moclobemide